Differences in maintenance chemotherapy among major cooperative groups
| Cooperative group . | Longer therapy for boys than girls in current generation of clinical trials . | Last year that boys were treated longer than girls in clinical trials* . | Total therapy duration in current generation of clinical trials, y . |
|---|---|---|---|
| AIEOP† | No | Never | 2 from diagnosis |
| BFM† | No | 1999 | 2 from diagnosis |
| BSPHO/CLCG-EORTC‡ | No | Never | 2 from EOI |
| COG | No | 2019 | 2 from start IM1 |
| COALL‡ | No | Never | 2 from EOI |
| DCOG‡ | No | Never | 2 from EOI |
| DFCI | No | 1991 | 2 from EOI |
| INS† | No | Never | 2 from diagnosis |
| JCCLSG | No | Never | 2 or 3 from diagnosis§ |
| MRC‡ | No | 2020‖ | 2 from EOI‖ |
| NOPHO‡ | No | Never | 2 from EOI |
| SFCE/FRALLE‡ | No | Never | 2-2.5 from diagnosis¶ |
| SJCRH | No | 2007 | 2.5 from diagnosis |
| TCCSG | No | Never | 2 or 3 from diagnosis# |
| TPOG | Yes, SR and HR B-ALL only | Current | 1.5 to ∼3 from diagnosis** |
| Cooperative group . | Longer therapy for boys than girls in current generation of clinical trials . | Last year that boys were treated longer than girls in clinical trials* . | Total therapy duration in current generation of clinical trials, y . |
|---|---|---|---|
| AIEOP† | No | Never | 2 from diagnosis |
| BFM† | No | 1999 | 2 from diagnosis |
| BSPHO/CLCG-EORTC‡ | No | Never | 2 from EOI |
| COG | No | 2019 | 2 from start IM1 |
| COALL‡ | No | Never | 2 from EOI |
| DCOG‡ | No | Never | 2 from EOI |
| DFCI | No | 1991 | 2 from EOI |
| INS† | No | Never | 2 from diagnosis |
| JCCLSG | No | Never | 2 or 3 from diagnosis§ |
| MRC‡ | No | 2020‖ | 2 from EOI‖ |
| NOPHO‡ | No | Never | 2 from EOI |
| SFCE/FRALLE‡ | No | Never | 2-2.5 from diagnosis¶ |
| SJCRH | No | 2007 | 2.5 from diagnosis |
| TCCSG | No | Never | 2 or 3 from diagnosis# |
| TPOG | Yes, SR and HR B-ALL only | Current | 1.5 to ∼3 from diagnosis** |
EOI, end of induction; HR, high risk; IM1, interim maintenance 1.
BFM, DFCI, and SJCRH only treated boys longer than girls in a single clinical trial.
Currently participating in AIEOP-BFM group trials.
Currently participating in ALLTogether group trials; AIEOP-BFM and ALLTogether both belong to the International BFM Study Group.
2 y for low risk and 3 y for SR, HR, and high HR.
Planned transition.
SR ∼2.5 y (104 wk after delayed intensification [DI]) and moderate risk/HR ∼2 y (76 wk after DI).
3 y for SR and ∼2 y for intermediate risk and HR.
146 wk for SR and HR boys, 120 wk for SR and HR girls, 74 wk for very HR boys and girls.